Seeking Alpha
Profile| Send Message| ()  

<< Return to Part 4

This is a continuation of my previous article on biotechnology stocks to watch ahead of ASCO 2012. In this article, I cover the final set of stocks that are presenting at ASCO 2012. Biotech stocks are high risk/reward stocks, and therefore considerable analysis is required before trading. Use this list as a potential starting point for your analysis.

1. Sanofi SA (SNY): Sanofi SA, formerly Sanofi-Aventis, is a global and diversified healthcare company. The company discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi focuses on the field of healthcare with six growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets and animal health. Sanofi has a portfolio of prescription drugs, vaccines, generics and consumer healthcare products.

On May 16, 2012, Sanofi announced abstracts spanning the company's innovative marketed and late-stage development compounds Zaltrap (aflibercept), Jevtana (cabazitaxel), SAR302503 (JAK2 inhibitor) and ombrabulin will be featured at the 2012 American Society of Clinical Oncology Annual Meeting.

The detail of the abstracts and schedule can be found here.

Sanofi has a market cap of $90.77 billion and it is currently trading around $34.31 with a 52-week range of $30.98 to $40.58. The stock has -6.10% price performance for the year 2012.

2. Amgen Inc (AMGN): Amgen is a biotechnology medicines company. The company discovers, develops, manufactures and markets medicines for illnesses. Its products are Neulasta (pegfilgrastim), a pegylated protein, based on the Filgrastim molecule, and NEUPOGEN (Filgrastim), a recombinant-methionyl human granulocyte colony-stimulating factor (G-CSF), both of which stimulate the production of neutrophils (a type of white blood cell that helps the body fight infection); Enbrel (etanercept), an inhibitor of tumor necrosis factor (TNF), a substance, which plays a role in the body's response to inflammatory diseases, and Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa), erythropoiesis-stimulating agents (ESAs).

Amgen will present its blinatumomab (AMG 103) Phase 2 study results during an oral abstract session at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) on June 4 (Abstract Number 6500; Oral Presentation, 8:00 AM - 8:15 AM CT, E354a).

The detail of the abstracts and schedule can be found here.

Amgen has a market cap of $53.70 billion and it is currently trading around $69.05 with a 52-week range of $47.66 to $72.00. The stock has 7.54% price performance for the year 2012.

3. Myriad Genetics, Inc (MYGN): Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests. It performs all of the molecular diagnostic testing and analysis for its tests in its own reference laboratory. Myriad's portfolio of nine molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a focus on improving an individual's decision making process for monitoring and treating disease.

On May 16, 2012, Myriad Genetics announced the presentation of a study at the American Society of Clinical Oncology Annual Meeting, including the complete results from a study titled, "Use of a proliferation-based mRNA signature to predict outcome in early-stage non-small cell lung adenocarcinoma." The abstract of the presentation (#7023) is available on the ASCO Meeting website.

Myriad Genetics has a market cap of $2.17 billion and it is currently trading around $25.53 with a 52-week range of $17.51 to $27.00. The stock has 21.92% price performance for the year 2012.

4. OncoGenex Pharmaceuticals Inc (OGXI): OncoGenex is a biopharmaceutical company engaged in the development and commercialization of cancer therapies. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. (TEVA) have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen, which is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. OGX-427 is in Phase 2 clinical development; OGX-225 is currently in pre-clinical development.

OncoGenex will present its additional preliminary results for ongoing OGX-427 study at the upcoming ASCO Annual Meeting in June 2012. Preliminary clinical data were already presented for OGX-427 for the treatment of prostate and bladder cancer at the American Society of Clinical Oncology Genitourinary Cancers Symposium in February 2012.

OncoGenex has a market cap of $189.31 million and it is currently trading around $13.02 with a 52-week range of $8.63 to $18.99. The stock has 10.9% price performance for the year 2012.

5. Optimer Pharmaceuticals, Inc (OPTR): Optimer is a biopharmaceutical company focused on developing and commercializing hospital specialty products. Optimer developed and commercialized DIFICID® (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer has also received marketing authorization for fidaxomicin tablets in theEuropean Union under the trade name DIFICLIR™. The company is seeking marketing authorization for fidaxomicin in Canada and is exploring marketing authorization in other parts of the world where C. difficile has emerged as a serious health problem, including Asia.

On May 16, 2012, Optimer announced the results of a retrospective subpopulation analysis of 183 patients with cancer from the company's two large Phase 3 trials, which showed the cancer patients with Clostridium difficile-associated diarrhea who were treated with DIFICID (fidaxomicin) tablets experienced resolution of their diarrheal symptoms approximately two days faster than those treated with oral vancomycin. These results will be presented on June 2 at the 2012 ASCO Annual Meeting.

The detail of the abstracts and schedule can be found here.

Optimer has a market cap of $720.81 million and it is currently trading around $15.32 with a 52-week range of $6.81 to $17.95. The stock has 25.16% price performance for the year 2012.

Some of the data is sourced from Google Finance, Yahoo Finance, Finviz, Fidelity and investors site.

Source: Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 5